![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Mazumder, N Neamati, JP Sommadossi, G Gosselin, RF Schinazi, JL Imbach and Y Pommier
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
We extended our previous study with 3'-azido-3'-deoxythymidine nucleotides [Proc. Natl. Acad. Sci. USA 91:5771-5775 (1994)] and examined the effects on human immunodeficiency virus type 1 (HIV-1) integrase of the nucleotides of three nucleoside analogues currently under evaluation in clinical trials: beta-D-2',3'-didehydro-3'- deoxythymidine, beta-D-2'-ara-fluoro-2', 3'-dideoxyadenosine, and beta- L-2',3'-dideoxy-3'-thiacytidine. Beta-D-2',3'-Didehydro-3'- deoxythymidine and beta-D-2'-ara-fluoro-2',3'-dideoxyadenosine nucleotides had IC50 values for strand transfer of 100 and 200 microM, respectively, whereas the corresponding 2',3'-dideoxynucleoside triphosphates, ddT triphosphate and ddA triphosphate, did not inhibit the integrase at 800 and 200 microM, respectively. Beta-L-2',3'-Dideoxy- 3'-thiacytidine triphosphate had no effect up to 500 microM. The L- enantiomers of 5-fluoro-2',3'-dideoxycytidine monophosphate and triphosphate had IC50 values of approximately 40 microM, whereas their D-enantiomer isomers showed no inhibition at 200 microM. NAD, pyridoxal phosphate, and coumermycin A1, which exhibit no antiviral activity but are typically used to probe nucleotide binding sites, were also tested. NAD was inactive, and its etheno derivative exhibited activity at 1 mM. In contrast, pyridoxal phosphate (IC50 = 18 microM and coumermycin A1 (IC50 = 5 microM were potent inhibitors. None of the coumermycin monomeric derivatives were active integrase inhibitors. The physiological ribonucleotides ATP and GTP inhibited HIV-1 integrase at or near cellular concentrations, suggesting that they may regulate HIV- 1 integrase activity in cells. In general, the active nucleotides tested inhibited binding of HIV-1 integrase to its substrate DNA an inhibited an integrase deletion mutant containing only amino acids 50- 212, indicating that nucleotides bind to the enzyme catalytic core. Consisently, the choice of nucleophile in the 3'-processing reaction was blocked to the same extent regardless of the nucleotide used (water, glycerol, or the viral DNA hydroxyl) by the enzyme. These observations suggest new strategies for antiviral drug development that could be based on nucleotide analogues as inhibitors of HIV-1 integrase.
This article has been cited by other articles:
|
|
 |
|
  K. L. Williams, Y. Zhang, N. Shkriabai, R. G. Karki, M. C. Nicklaus, N. Kotrikadze, S. Hess, S. F. J. Le Grice, R. Craigie, V. K. Pathak, et al. Mass Spectrometric Analysis of the HIV-1 Integrase-Pyridoxal 5'-Phosphate Complex Reveals a New Binding Site for a Nucleotide Inhibitor J. Biol. Chem., March 4, 2005; 280(9): 7949 - 7955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shkriabai, S. S. Patil, S. Hess, S. R. Budihas, R. Craigie, T. R. Burke Jr., S. F. J. Le Grice, and M. Kvaratskhelia Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry PNAS, May 4, 2004; 101(18): 6894 - 6899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Jing, E. De Clercq, R. F. Rando, L. Pallansch, C. Lackman-Smith, S. Lee, and M. E. Hogan Stability-Activity Relationships of a Family of G-tetrad Forming Oligonucleotides as Potent HIV Inhibitors. A BASIS FOR ANTI-HIV DRUG DESIGN J. Biol. Chem., February 4, 2000; 275(5): 3421 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Zhu, M. L. Cordeiro, J. Atienza, W. E. Robinson Jr., and S. A. Chow Irreversible Inhibition of Human Immunodeficiency Virus Type 1 Integrase by Dicaffeoylquinic Acids J. Virol., April 1, 1999; 73(4): 3309 - 3316. [Abstract] [Full Text]
|
|
|
|
|
|
N. Jing and M. E. Hogan Structure-Activity of Tetrad-forming Oligonucleotides as a Potent Anti-HIV Therapeutic Drug J. Biol. Chem., December 25, 1998; 273(52): 34992 - 34999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Farnet, B. Wang, M. Hansen, J. R. Lipford, L. Zalkow, W. E. Robinson Jr., J. Siegel, and F. Bushman Human Immunodeficiency Virus Type 1 cDNA Integration: New Aromatic Hydroxylated Inhibitors and Studies of the Inhibition Mechanism Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2245 - 2253. [Abstract] [Full Text]
|
|
|
|
|
|
R. R. Drake, N. Neamati, H. Hong, A. A. Pilon, P. Sunthankar, S. D. Hume, G. W. A. Milne, and Y. Pommier Identification of a nucleotide binding site in HIV-1 integrase PNAS, April 14, 1998; 95(8): 4170 - 4175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Acel, B. E. Udashkin, M. A. Wainberg, and E. A. Faust Efficient Gap Repair Catalyzed In Vitro by an Intrinsic DNA Polymerase Activity of Human Immunodeficiency Virus Type 1 Integrase J. Virol., March 1, 1998; 72(3): 2062 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Neamati, H. Hong, S. Sunder, G. W. A. Milne, and Y. Pommier Potent Inhibitors of Human Immunodeficiency Virus Type 1 Integrase: Identification of a Novel Four-Point Pharmacophore and Tetracyclines as Novel Inhibitors Mol. Pharmacol., December 1, 1997; 52(6): 1041 - 1055. [Abstract] [Full Text]
|
|
|
|
|
|
P. Cherepanov, J. A. Esté, R. F. Rando, J. O. Ojwang, G. Reekmans, R. Steinfeld, G. David, E. De Clercq, and Z. Debyser Mode of Interaction of G-Quartets with the Integrase of Human Immunodeficiency Virus Type 1 Mol. Pharmacol., November 1, 1997; 52(5): 771 - 780. [Abstract] [Full Text]
|
|
|
|
|
|
A. Mazumder, H. Uchida, N. Neamati, S. Sunder, M. Jaworska-Maslanka, E. Wickstrom, F. Zeng, R. A. Jones, R. F. Mandes, H. K. Chenault, et al. Probing Interactions between Viral DNA and Human Immunodeficiency Virus Type 1 Integrase Using Dinucleotides Mol. Pharmacol., April 1, 1997; 51(4): 567 - 575. [Abstract] [Full Text]
|
|
|
|
|
|
A. Mazumder, N. Neamati, A. A. Pilon, S. Sunder, and Y. Pommier Chemical Trapping of Ternary Complexes of Human Immunodeficiency Virus Type 1Integrase, Divalent Metal, and DNA Substrates Containing an Abasic Site. IMPLICATIONS FOR THE ROLE OF LYSINE 136IN DNA BINDING J. Biol. Chem., November 1, 1996; 271(44): 27330 - 27338. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
